Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

The Immune Microenvironment and Cancer Metastasis.

El-Kenawi A, Hänggi K, Ruffell B.

Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a037424. doi: 10.1101/cshperspect.a037424. [Epub ahead of print]

PMID:
31501262
2.

Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer.

El-Kenawi A, Gatenbee C, Robertson-Tessi M, Bravo R, Dhillon J, Balagurunathan Y, Berglund A, Visvakarma N, Ibrahim-Hashim A, Choi J, Luddy K, Gatenby R, Pilon-Thomas S, Anderson A, Ruffell B, Gillies R.

Br J Cancer. 2019 Oct;121(7):556-566. doi: 10.1038/s41416-019-0542-2. Epub 2019 Aug 16.

PMID:
31417189
3.

AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.

Trillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido Á, Gilvary DL, Anadon CM, Costich TL, Wei S, Flores ER, Ruffell B, Conejo-Garcia JR, Rodriguez PC.

Cancer Res. 2019 Oct 1;79(19):5034-5047. doi: 10.1158/0008-5472.CAN-19-0880. Epub 2019 Aug 13.

PMID:
31409640
4.

Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer.

Hänggi K, Ruffell B.

Cancer Cell. 2019 Apr 15;35(4):535-537. doi: 10.1016/j.ccell.2019.03.008.

PMID:
30991021
5.

Macrophages as regulators of tumour immunity and immunotherapy.

DeNardo DG, Ruffell B.

Nat Rev Immunol. 2019 Jun;19(6):369-382. doi: 10.1038/s41577-019-0127-6. Review.

PMID:
30718830
6.

Mucosal Immunity in the Female Murine Mammary Gland.

Betts CB, Pennock ND, Caruso BP, Ruffell B, Borges VF, Schedin P.

J Immunol. 2018 Jul 15;201(2):734-746. doi: 10.4049/jimmunol.1800023. Epub 2018 Jun 8.

7.

Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.

Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA.

Breast Cancer Res Treat. 2018 Sep;171(2):283-293. doi: 10.1007/s10549-018-4835-6. Epub 2018 Jun 1.

PMID:
29858753
8.

moDCs, Less Problems.

Gardner A, Ruffell B.

Immunity. 2018 Jan 16;48(1):6-8. doi: 10.1016/j.immuni.2017.12.017.

9.

TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.

de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B.

Cancer Cell. 2018 Jan 8;33(1):60-74.e6. doi: 10.1016/j.ccell.2017.11.019.

10.

Inflammation, ROS, and Mutagenesis.

El-Kenawi A, Ruffell B.

Cancer Cell. 2017 Dec 11;32(6):727-729. doi: 10.1016/j.ccell.2017.11.015.

11.

Reducing interferon'ce in stem cells.

Gardner A, Ruffell B.

Nat Cell Biol. 2017 May 31;19(6):597-599. doi: 10.1038/ncb3544.

PMID:
28561058
12.

Dendritic Cells and Cancer Immunity.

Gardner A, Ruffell B.

Trends Immunol. 2016 Dec;37(12):855-865. doi: 10.1016/j.it.2016.09.006. Epub 2016 Oct 25. Review.

13.

Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models.

Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA.

Oncotarget. 2016 Dec 13;7(50):82482-82492. doi: 10.18632/oncotarget.12694.

14.

Erratum to: Intellectual disability health content within medical curriculum: an audit of what our future doctors are taught.

Trollor JN, Ruffell B, Tracy J, Torr JJ, Durvasula S, Iacono T, Eagleson C, Lennox N.

BMC Med Educ. 2016 Oct 5;16(1):260. No abstract available.

15.

Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.

Bergstrom CP, Ruffell B, Ho CM, Higano CS, Ellis WJ, Garzotto M, Beer TM, Graff JN.

Anticancer Drugs. 2017 Jan;28(1):120-126.

PMID:
27669423
16.

Tipping the Balancing ACT.

Pilon-Thomas S, Ruffell B.

Cancer Cell. 2016 Sep 12;30(3):367-368. doi: 10.1016/j.ccell.2016.08.012.

17.

Immune Regulation of the Metastatic Process: Implications for Therapy.

de Mingo Pulido A, Ruffell B.

Adv Cancer Res. 2016;132:139-63. doi: 10.1016/bs.acr.2016.05.004. Epub 2016 Jun 17. Review.

18.

Intellectual disability health content within medical curriculum: an audit of what our future doctors are taught.

Trollor JN, Ruffell B, Tracy J, Torr JJ, Durvasula S, Iacono T, Eagleson C, Lennox N.

BMC Med Educ. 2016 Apr 11;16:105. doi: 10.1186/s12909-016-0625-1. Erratum in: BMC Med Educ. 2016 Oct 5;16(1):260.

19.

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.

Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, Massengill C, Noyes DR, Martinez GV, Afzal R, Chen Z, Ren X, Antonia SJ, Haura EB, Ruffell B, Beg AA.

Clin Cancer Res. 2016 Aug 15;22(16):4119-32. doi: 10.1158/1078-0432.CCR-15-2584. Epub 2016 Mar 10.

20.

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM.

Cancer Discov. 2016 Mar;6(3):270-85. doi: 10.1158/2159-8290.CD-15-0827. Epub 2015 Dec 29. Erratum in: Cancer Discov. 2016 Jul;6(7):802.

21.

Monocytes promote liver carcinogenesis in an oncogene-specific manner.

Juric V, Ruffell B, Evason KJ, Hu J, Che L, Wang L, Chen X, Bishop JM.

J Hepatol. 2016 Apr;64(4):881-90. doi: 10.1016/j.jhep.2015.11.025. Epub 2015 Nov 27.

22.

Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.

Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA.

Breast Cancer Res Treat. 2015 Dec;154(3):495-508. doi: 10.1007/s10549-015-3645-3. Epub 2015 Nov 21.

23.

Macrophages and therapeutic resistance in cancer.

Ruffell B, Coussens LM.

Cancer Cell. 2015 Apr 13;27(4):462-72. doi: 10.1016/j.ccell.2015.02.015. Epub 2015 Apr 6. Review.

24.

TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM.

Cancer Immunol Res. 2015 May;3(5):518-25. doi: 10.1158/2326-6066.CIR-14-0232. Epub 2015 Feb 25.

25.

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM.

Cancer Cell. 2014 Nov 10;26(5):623-37. doi: 10.1016/j.ccell.2014.09.006. Epub 2014 Oct 16.

26.

B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.

Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM.

Cancer Cell. 2014 Jun 16;25(6):809-821. doi: 10.1016/j.ccr.2014.04.026. Epub 2014 Jun 5.

27.

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, Daniel D.

Oncoimmunology. 2013 Dec 1;2(12):e26968. Epub 2013 Dec 4.

28.

Cathepsin C is a tissue-specific regulator of squamous carcinogenesis.

Ruffell B, Affara NI, Cottone L, Junankar S, Johansson M, DeNardo DG, Korets L, Reinheckel T, Sloane BF, Bogyo M, Coussens LM.

Genes Dev. 2013 Oct 1;27(19):2086-98. doi: 10.1101/gad.224899.113. Epub 2013 Sep 24.

29.

Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.

Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Lau J, Jablons DM, Coussens LM.

J Immunol. 2013 Aug 15;191(4):2009-17. doi: 10.4049/jimmunol.1301317. Epub 2013 Jul 12. Erratum in: J Immunol. 2013 Nov 15;191(10):5319. Beltran, Adam [corrected to Yagui-Beltrán, Adam].

30.

Some DCs are "B"etter.

Ruffell B, Coussens LM.

Immunity. 2013 Apr 18;38(4):626-8. doi: 10.1016/j.immuni.2013.03.011.

31.

Differential macrophage programming in the tumor microenvironment.

Ruffell B, Affara NI, Coussens LM.

Trends Immunol. 2012 Mar;33(3):119-26. doi: 10.1016/j.it.2011.12.001. Epub 2012 Jan 23. Review.

32.

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM.

Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1.

33.

Leukocyte composition of human breast cancer.

Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801. doi: 10.1073/pnas.1104303108. Epub 2011 Aug 8.

34.

MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles.

Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, Rao J, Tikhomirov GA, Wendland MF, Corot C, Coussens LM.

Clin Cancer Res. 2011 Sep 1;17(17):5695-704. doi: 10.1158/1078-0432.CCR-10-3420. Epub 2011 Jul 26.

35.

Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in Inflammatory and Interleukin 4-activated Macrophages.

Ruffell B, Poon GF, Lee SS, Brown KL, Tjew SL, Cooper J, Johnson P.

J Biol Chem. 2011 Jun 3;286(22):19179-90. doi: 10.1074/jbc.M110.200790. Epub 2011 Apr 6.

36.

Histamine restricts cancer: nothing to sneeze at.

Ruffell B, Coussens LM.

Nat Med. 2011 Jan;17(1):43-4. doi: 10.1038/nm0111-43. No abstract available.

PMID:
21217680
37.

Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Ruffell B, DeNardo DG, Affara NI, Coussens LM.

Cytokine Growth Factor Rev. 2010 Feb;21(1):3-10. doi: 10.1016/j.cytogfr.2009.11.002. Epub 2009 Dec 11. Review.

38.

CD44 and its role in inflammation and inflammatory diseases.

Johnson P, Ruffell B.

Inflamm Allergy Drug Targets. 2009 Jul;8(3):208-20. Review.

PMID:
19601881
39.

Hyaluronan induces cell death in activated T cells through CD44.

Ruffell B, Johnson P.

J Immunol. 2008 Nov 15;181(10):7044-54.

40.

Chondroitin sulfate addition to CD44H negatively regulates hyaluronan binding.

Ruffell B, Johnson P.

Biochem Biophys Res Commun. 2005 Aug 26;334(2):306-12.

PMID:
16002044
41.

Role of CD44 and hyaluronan in neutrophil recruitment.

Khan AI, Kerfoot SM, Heit B, Liu L, Andonegui G, Ruffell B, Johnson P, Kubes P.

J Immunol. 2004 Dec 15;173(12):7594-601.

Supplemental Content

Loading ...
Support Center